Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Other Intangible Assets

Schedule of carrying value of goodwill

	Goodwill
December 31, 2017	$	187,173
Impairments		(86,318)
December 31, 2018	$	100,855
Impairments		—
December 31, 2019	$	100,855

Schedule of major categories of the Company’s intangible assets and the weighted average remaining amortization period

	December 31, 2019
									Weighted
									Average
									Remaining
	Gross						Net		Amortization
	Carrying		Accumulated				Carrying		Period
	Amount		Amortization		Impairment		Amount		(Years)
Distribution Rights	$	98,433	$	(22,291)	$	(64,719)	$	11,423	10.1
Product Rights		348,600		(152,348)		(146,033)		50,219	3.1
Tradenames		13,485		(3,035)		—		10,450	15.0
Developed Technology		125,461		(34,572)		(72,995)		17,894	10.9
IPR&D		64,000		—		—		64,000	Indefinite Lived
	$	649,979	$	(212,246)	$	(283,747)	$	153,986

	December 31, 2018
									Weighted
									Average
	Gross						Net		Remaining
	Carrying		Accumulated				Carrying		Amortization
	Amount		Amortization		Impairment		Amount		Period (Years)
Distribution Rights	$	98,433	$	(17,229)	$	—	$	81,204	12.0
Product Rights		326,530		(109,057)		—		217,473	4.0
Tradenames		13,485		(2,329)		—		11,156	16.0
Developed Technology		138,134		(30,974)		(10,303)		96,857	12.6
IPR&D		91,300		—		(7,600)		83,700	Indefinite Lived
	$	667,882	$	(159,589)	$	(17,903)	$	490,390

Schedule of changes in the net carrying amount of intangible assets

	Distribution		Product				Developed
	Rights		Rights		Tradenames		Technology		IPR&D		Total
December 31, 2017	$	88,543	$	276,628	$	11,862	$	117,056	$	91,300	$	585,389
Amortization		(7,339)		(59,155)		(706)		(9,896)		—		(77,096)
Impairments		—		—		—		(10,303)		(7,600)		(17,903)
December 31, 2018	$	81,204	$	217,473	$	11,156	$	96,857	$	83,700	$	490,390
Amortization		(5,062)		(40,921)		(706)		(5,968)		—		(52,657)
Impairments		(64,719)		(146,033)		—		(72,995)		—		(283,747)
Reclassifications(A)		—		19,700		—		—		(19,700)		—
December 31, 2019	$	11,423	$	50,219	$	10,450	$	17,894	$	64,000	$	153,986

^(A) IPR&D in the amount of $19.7 million related to Osmolex ER was reclassified to Product Rights in the first quarter of 2019 when the product was launched.  Osmolex ER was fully impaired during the second quarter of 2019.

Schedule of expected amortization expense

	Amortization
Years ending December 31	Expense
2020	$	17,450
2021		17,161
2022		12,685
2023		11,805
2024		10,682
Thereafter		20,203
Total	$	89,986